UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Blood, 2021-11, Vol.138 (Supplement 1), p.2043-2043

2021

Volltextzugriff (PDF)

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Blood, 2022-11, Vol.140 (Supplement 1), p.5426-5427

2022

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers

Blood, 2016-12, Vol.128 (22), p.1263-1263

2016

Volltextzugriff (PDF)

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

Cancer chemotherapy and pharmacology, 2003-04, Vol.51 (4), p.297-305

2003

Volltextzugriff (PDF)

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

Clinical pharmacology in drug development, 2019-02, Vol.8 (2), p.246-259

2019

Volltextzugriff (PDF)

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

Blood, 2015-12, Vol.126 (23), p.4548-4548

2015

Volltextzugriff (PDF)

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Blood, 2016-12, Vol.128 (22), p.2452-2452

2016

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Blood, 2016-12, Vol.128 (22), p.1264-1264

2016

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Blood, 2015-12, Vol.126 (23), p.3336-3336

2015

Volltextzugriff (PDF)

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Blood, 2014-12, Vol.124 (21), p.4007-4007

2014

Volltextzugriff (PDF)

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

The Journal of experimental medicine, 1996-06, Vol.183 (6), p.2681-2686

1996

Volltextzugriff (PDF)

Out of Place

The Georgia review, 1988-10, Vol.42 (3), p.555-566

Merica, Elizabeth

1988

Volltextzugriff (PDF)

Visualization of Specific B and T Lymphocyte Interactions in the Lymph Node

Science (American Association for the Advancement of Science), 1998-07, Vol.281 (5373), p.96-99

1998

Volltextzugriff (PDF)

Intrauterine growth restriction transiently delays alveolar formation and disrupts retinoic acid receptor expression in the lung of female rat pups

Pediatric research, 2013-05, Vol.73 (5), p.612-620

2013

Volltextzugriff (PDF)

Use of adoptive transfer of T-cell antigen-receptor-transgenic T cells for the study of T-cell activation in vivo

Immunological reviews, 1997-04, Vol.156 (1), p.67-78

1997

Volltextzugriff (PDF)

A study on biological effects of low-intensity millimeter waves

IEEE transactions on plasma science, 2002-08, Vol.30 (4), p.1489-1496

2002

Volltextzugriff (PDF)

A study on biological effects of low-intensity millimeter waves: Special issue on nonthermal medical/biological applications of ionized gases and electromagnetic fields

IEEE transactions on plasma science, 2002, Vol.30 (4), p.1489-1496

2002

Volltextzugriff (PDF)

Antigen‐Specific CD4+ T Cells that Survive after the Induction of Peripheral Tolerance Possess an Intrinsic Lymphokine Production Defect

Novartis Foundation Symposium 215 ‐ Immunological Tolerance, 2007, p.103-119

2007

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(18)
Buchkapitel
(1)

Sprache

Englisch
(19)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Life Sciences & Biomedicine
(5)
Biological And Medical Sciences
(3)
Female
(3)
Humans
(3)
Immunology
(3)
Animals
(2)
Dose-Response Relationship, Drug
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Male
(2)
Middle Aged
(2)
Pharmacology & Pharmacy
(2)
Absorption
(1)
Adenocarcinoma - Drug Therapy
(1)
Adenocarcinoma - Metabolism
(1)
Adenocarcinoma - Pathology
(1)
Adoptive Transfer
(1)
Adult
(1)
Aged
(1)
Aged, 80 And Over
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

Out of Place

Visualization of Specific B and T Lymphocyte Interactions in the Lymph Node

Intrauterine growth restriction transiently delays alveolar formation and disrupts retinoic acid receptor expression in the lung of female rat pups

Use of adoptive transfer of T-cell antigen-receptor-transgenic T cells for the study of T-cell activation in vivo

A study on biological effects of low-intensity millimeter waves

A study on biological effects of low-intensity millimeter waves: Special issue on nonthermal medical/biological applications of ionized gases and electromagnetic fields

Antigen‐Specific CD4+ T Cells that Survive after the Induction of Peripheral Tolerance Possess an Intrinsic Lymphokine Production Defect

Suchergebnisse filtern